Analysts Expect VBI Vaccines Inc (NASDAQ:VBIV) Will Announce Quarterly Sales of $360,000.00

Equities research analysts expect VBI Vaccines Inc (NASDAQ:VBIV) to post sales of $360,000.00 for the current quarter, according to Zacks. Two analysts have issued estimates for VBI Vaccines’ earnings, with estimates ranging from $210,000.00 to $500,000.00. VBI Vaccines reported sales of $650,000.00 in the same quarter last year, which indicates a negative year over year growth rate of 44.6%. The business is expected to announce its next earnings results on Wednesday, November 4th.

On average, analysts expect that VBI Vaccines will report full year sales of $1.42 million for the current year, with estimates ranging from $1.13 million to $1.70 million. For the next year, analysts forecast that the business will post sales of $5.26 million, with estimates ranging from $4.10 million to $6.42 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings data on Friday, July 31st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.04). The business had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.86 million. VBI Vaccines had a negative return on equity of 46.47% and a negative net margin of 2,467.47%.

VBIV has been the subject of several recent analyst reports. Raymond James upgraded VBI Vaccines from an “outperform” rating to a “strong-buy” rating and lifted their price target for the company from $8.00 to $9.00 in a research note on Wednesday, August 26th. ValuEngine lowered VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. BMO Capital Markets restated a “buy” rating and issued a $4.00 price target on shares of VBI Vaccines in a research note on Monday, June 29th. Oppenheimer restated a “buy” rating and issued a $8.00 price target on shares of VBI Vaccines in a research note on Thursday, August 27th. Finally, Zacks Investment Research lowered VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Saturday, July 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $5.30.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VBIV. BlackRock Inc. boosted its stake in VBI Vaccines by 13.0% in the first quarter. BlackRock Inc. now owns 11,678,848 shares of the biopharmaceutical company’s stock valued at $11,095,000 after acquiring an additional 1,341,519 shares in the last quarter. SG Americas Securities LLC boosted its stake in VBI Vaccines by 296.1% in the first quarter. SG Americas Securities LLC now owns 55,099 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 41,189 shares in the last quarter. Rhumbline Advisers boosted its stake in VBI Vaccines by 45.6% in the first quarter. Rhumbline Advisers now owns 103,370 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 32,395 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in VBI Vaccines by 193.1% in the first quarter. Bank of New York Mellon Corp now owns 475,054 shares of the biopharmaceutical company’s stock valued at $451,000 after acquiring an additional 312,960 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its stake in VBI Vaccines by 64.8% in the first quarter. Oppenheimer & Co. Inc. now owns 26,200 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 10,300 shares in the last quarter. Institutional investors own 42.59% of the company’s stock.

Shares of NASDAQ VBIV traded down $0.12 during trading on Monday, reaching $2.96. 6,925,462 shares of the company traded hands, compared to its average volume of 10,427,736. The company has a current ratio of 5.86, a quick ratio of 5.77 and a debt-to-equity ratio of 0.13. VBI Vaccines has a 12-month low of $0.47 and a 12-month high of $6.93. The firm’s fifty day simple moving average is $3.55 and its 200 day simple moving average is $2.62. The stock has a market cap of $684.35 million, a P/E ratio of -11.38 and a beta of 1.79.

VBI Vaccines Company Profile

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Read More: What is the Current Ratio?

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.